Microbiology at first visit of moderate-to-severe diabetic foot infection with antimicrobial activity and a survey of quinolone monotherapy

Diabetes Research and Clinical Practice

Volumn 94, Issue 1, 2011, Pages 133-139

  Tascini, Carlo ^a   Piaggesi, Alberto ^a   Tagliaferri, Enrico ^a   Iacopi, Elisabetta ^a   Fondelli, Serena ^a   Tedeschi, Anna ^a   Rizzo, Loredana ^a   Leonildi, Alessandro ^a   Menichetti, Francesco ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Antibiotic susceptibility; DFI; Microbiology; Quinolones

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; NETILMICIN; OXACILLIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; ULIFLOXACIN; UNINDEXED DRUG; VANCOMYCIN;

ADULT; AGED; ANAEROBE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; CONTROLLED STUDY; DIABETIC FOOT; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENTEROBACTERIACEAE; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; NONHUMAN; PROTEUS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; WOUND INFECTION;

ANTI-INFECTIVE AGENTS; CANDIDA; DIABETIC FOOT; DOXYCYCLINE; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; QUINOLONES; RIFAMPIN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; VANCOMYCIN;

EID: 80054905001     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.07.017     Document Type: Article

References (31)

1. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
2. Haslam D.W., James W.P. Obesity. Lancet 2005, 366:1197-1209.
3. Mancini L., Ruotolo V. Diabetic foot: epidemiology. Rays 1997, 22(October-December (4)):511-523.
4. Dang C.N., Prasad Y.D., Boulton A.J., Jude E.B. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 2003, 20:159-161.
5. Gadepalli R., Dhawan B., Sreenivas V., Kapil A., Ammini A.C., Chaudhry R. A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care 2006, 29:1727-1732.
6. Abdulrazak A., Bitar Z.I., Al-Shamali A.A., Mobasher L.A. Bacteriological study of diabetic foot infections. J Diabetes Complications 2005, (19):138-141.
7. Armstrong D.G., Liswood P.J., Todd W.F., William J. Stickel Bronze Award. Prevalence of mixed infections in the diabetic pedal wound. A retrospective review of 112 infections. J Am Podiatr Med Assoc 1995, 85:533-537.
8. Citron D.M., Goldstein E.J., Merriam C.V., Lipsky B.A., Abramson M.A. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007, (September):2819-2828.
9. Bowler P.G., Duerden B.I., Armstrong D.G. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 2001, 14:244-269.
10. Diamantopoulos E.J., Haritos D., Yfandi G., Grigoriadou M., Margariti G., Paniara O., et al. Management and outcome of severe diabetic foot infections. Exp Clin Endocrinol Diabetes 1998, 106:346-352.
11. Gu J., Li H., Li M., Vuong C., Otto M., Wen Y., et al. Bacterial insertion sequence IS 256 as a potential molecular marker to discriminate invasive strains from commensal strains of S. epidermidis. J Hosp Infect 2005, 61:342-348.
12. Lipsky B.A., Giordano P., Choudhri S., Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother 2007, 60:370-376.
13. Oberdorfer K., Swoboda S., Hamann A., Baertsch U., Kusterer K., Born B., et al. Tissue and serum levofloxacin concentrations in diabetic foot infection patients. J Antimicrob Chemother 2004, 54:836-839.
14. Apelqvist J., Bakker K., van Houtum W.H., Schaper N.C. International Working Group on the Diabetic Foot (IWGDF) Editorial Board. Practical guidelines on the management and prevention of the diabetic foot: based upon the International Consensus on the Diabetic Foot (2007). Prepared by the International Working Group on the Diabetic Foot. Diabetes Metab Res Rev 2008, 24(May-June (Suppl. 1)):S181-S187.
15. Armstrong D.G., Lavery L.A., Harkless L.B. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998, 21(May (5)):855-859.
16. Senneville E., Melliez H., Beltrand E., Legout L., Valette M., Cazaubiel M., et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clin Infect Dis 2006, 42:57-62.
17. Jorgensen J.H., Turnidge J.D., Washington J.A. Antibacterial susceptibility tests: dilution and disk diffusion methods. Manual of clinical microbiology 1999, 526-577. American Society for Microbiology, Washington, DC. 7th ed. P.R. Murray, E.J. Baron, M.A. Pfaller, F.C. Tenover, R.H. Yolken (Eds.).
18. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; 18th informational supplement 2008, Clinical Laboratory Standards Institute, Wayne, PA.
19. Dunne W.M., Hardin D.J. Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp. J Clin Microbiol 2005, (December):5945-5949.
20. Huycke M.M., Joyce W., Wack M.F. Augmented production of extracellular superoxide by blood isolates of Enterococcus faecalis. J Infect Dis 1996, 173(March (3)):743-746.
21. IDSA Guidelines Diagnosis and treatment of diabetic foot infection. CID 2004:39.
22. Zia I., Vu V., Hester M., Cheriyath P., Marks J., Grossman A.B., et al. Prevalence of MRSA in diabetic foot infections in a community teaching hospital. Foot 2011, 21(March (1)):53.
23. European Antimicrobial Resistance Surveillance System. EARSS Annual Report 2008.
24. Mugnaioli C., Luzzaro F., De Luca F., Brigante G., Perilli M., Amicosante G., et al. CTX-M-type extended-spectrum beta-lactamases in Italy: molecular epidemiology of an emerging countrywide problem. Antimicrob Agents Chemother 2006, 50(August (8)):2700-2706.
25. Rossolini G.M., Luzzaro F., Migliavacca R., Mugnaioli C., Pini B., De Luca F., et al. First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. Antimicrob Agents Chemother 2008, 52(November (11)):4023-4029. [Epub 2008 September 22].
26. Ramakant P., Verma A.K., Misra R., Prasad K.N., Chand G., Mishra A., et al. Changing microbiological profile of pathogenic bacteria in diabetic foot infections: time for a rethink on which empirical therapy to choose?. Diabetologia 2011, 54(1):58-64.
27. Walsh T.R., Weeks J., Livermore D.M., Toleman M.A. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011, 11(May (5)):355-362. [Epub 2011 April 7].
28. Missoni E.M., Kalenić S., Vukelić M., De Syo D., Belicza M., Kern J., et al. Role of yeasts in diabetic foot ulcer infection. Acta Med Croatica 2006, 60(1):43-50.
29. Zubair M., Malik A., Ahmad J., Rizvi M., Farooqui K.J., Rizvi M.W. A study of biofilm production by gram-negative organisms isolated from diabetic foot ulcer patients. Biol Med 2011, 3(2):147-157. [Special Issue].
30. Allen G.P., Kaatz G.W., Rybak M.J. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones againstStaphylococcus aureusin a pharmacodynamicmodel. Int J Antimicrob Agents 2004, 24(August (2)):150-160.
31. Firsov A.A., Vostrov S.N., Lubenko I.Y., Drlica K., Portnoy Y.A., Zinner S.H. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003, (May):1604-1613.